STTKShattuck Labs, Inc.
Pharmaceutical Preparations
- Revenue
- $1M
- 83% YoY
- Operating margin
- -5150.8%
- 266% YoY
- EBITDA
- −$48M
- 38% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired700% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $30M | $652K | $2M | $6M | $1M | 83% |
| Operating income | −$45M | −$103M | −$92M | −$81M | −$52M | 36% |
| Net income | −$45M | −$102M | −$87M | −$75M | −$49M | 35% |
| Operating cash flow | −$57M | −$94M | −$81M | −$61M | −$40M | 34% |
| Capex | $8M | $12M | $407K | $59K | $71K | 20% |
| Stock-based comp | $5M | $6M | $7M | $10M | $7M | 27% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $3M | 51 | — |
| FY2024 | $3M | $1M | 17 | — |